• 

  Huw Jones

  CEO of Evgen Pharma Plc

This hour-long session will feature two interviews with life sciences entrepreneurs/business leaders who have achieved success, but will reflect on the highs, lows, and challenges they have experienced and overcome throughout their career. The interviews will look at all aspects of business success, not just the science, but team and Board, investment, strategy, stages of growth, location, culture, and your place in the wider business ecosystem.

Emma Palmer Foster will be Interviewing Harry Destecroix, Co-Founder, Science Creates & Jason Mellad, CEO Start Codon

• 

  Harry Destecroix

  General Partner & Co-Founder of Science Creates Ventures
• 

  Jason Mellad

  CEO of Start Codon
• 

  Emma Palmer Foster

  Strategic Communications Consultant at The Oxford Science Park

Sponsored by Thermo Fisher Scientific

Innovation in clinical trial design is transforming evidence generation in drug development, focusing on the effectiveness of clinical trials whilst maintaining high quality data for regulatory decision-making. Our expert speakers will expand on the advantages of the different approaches to help you identify the best and most cost-effective trials strategies for your business, including:

• Adaptive designs allowing trial modifications
• Master protocols designed to address questions in multiple diseases
• Enrichment designs tailoring treatments to those patients who will benefit most
• Umbrella Trials evaluating multiple investigational drugs administered as combinations
• Basket Trials studying a single therapy in multiple diseases or disease subtypes
• Platform Trials evaluating multiple therapies in a single disease in an open-ended format
• Historical control, where old data is used to compare with new data from new trials

• 

  Catherine Beech

  CEO of Exonate Limited
• 

  Antimo Fiorillo

  Founder & CEO of Allyfe
• 

  Javier Jimenez

  EVP Transformational Design at Syneos Health
• 

  Emma Tinsley

  CEO of Weatherden
• 

  Helen Underwood

  Director, Strategic Client Relationships of Fisher Clinical Services UK

During this session, Paul Edwards, Board Member of OBN will interview Dr Rafaele Tordjman, CEO of Jeito on a range of matters including:

• A broad update on Life Sciences investment trends and projections in Europe
• How has your investment philosophy evolved – and is this reflected in the wider industry?
• What are the typical timelines to exit and is this changing?
• What aspects are particularly attractive to investors?

• 

  Rafaèle Tordjman

  Founder & CEO of JEITO

This session will feature a broad update on a range of matters, all useful for UK companies seeking growth opportunities in the US bio market, including:
• How to leverage academic and R&D services to boost your capabilities and offering to the industry
• how to secure the right talent and regional know-how to help support growth and maximise opportunities for your growing business
• Practical and up-to-date advice from the Department of Industry & Trade
• real-life case study insight into the opportunities and challenges involved in a move into the US Market, from a company owner who has first-hand experience

• 

  Rose Adedeji

  US Expansion Advisor at Foothold America
• 

  John Catravas

  Professor at Old Dominion University, Virginia
• 

  Charles Macdowell

  Business Development Representative at VA Beach Bio
• 

  Matthew Segall

  CEO of Optibrium
• 

  Hannah Williams

  Deputy Head of Life Sciences at Department for International Trade

Research & Development Tax Credits are a valuable benefit for many research-intensive companies and not dependent on shareholders or similar stakeholders.

Our expert speaker, Katy Rabindran will take us through the key issues and help guide you as to whether R&D tax credits could be a valuable financial support for your life sciences business.

• 

  Katy Rabindran

  Senior Manager at BDO